<ul data-eligibleForWebStory="false"><li>Solara Active Pharma Sciences is undergoing a strategic transformation focusing on regulated global markets and value-added products, leading to a surge in investor confidence with its stock rising by 34% over the past month.</li><li>The company specializes in manufacturing APIs for various therapeutic areas, including anti-inflammatory and anti-infective segments, and offers Contract Research and Manufacturing Services (CRAMS) to other pharmaceutical firms.</li><li>Solara plans to demerge its CRAMS and Polymers businesses to create a new entity named Synthix Global Pharma Solutions, aiming to unlock significant value and drive rapid expansion, targeting a turnover growth to Rs 500 crores within the next 3-4 years.</li><li>While facing operational challenges in FY25 due to market headwinds, Solara is focused on strengthening its balance sheet by reducing debt and aims to achieve a net debt/EBITDA of 1.7–1.8x by Q1 FY27, with optimistic revenue and EBITDA growth projections for FY26.</li></ul>

Solara Active Pharma Sciences: A Strategic Shift Towards High-Value Growth

Discover more